Benjamin Silas Daniel

Benjamin Silas Daniel

Auto-generated profile, based on publicly available information

Benjamin Silas Daniel

Department of Dermatology Royal Children's Hospital Melbourne Parkville Victoria Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
SBStephanie Clare Blake
Stephanie Clare Blake
BDBenjamin Silas Daniel
Benjamin Silas Daniel
Knowledge with regard to the pathogenesis of lupus erythematosus has progressed rapidly over the past decade, and with it has come promising new agents for the treatment of cutaneous lupus erythematous (CLE). Classification of CLE is performed using clinical features and histopathologic findings, and is crucial for determining prognosis and choosing therapeutic options. Preventative therapy is critical in achieving optimal disease control, and patients should be counseled on sun-safe behavior and smoking cessation. First-line therapy includes topical corticosteroids and calcineurin inhibitors, with antimalarial therapy. Traditionally, refractory disease was treated with oral retinoids, dapsone, and other oral immunosuppressive drugs, but new therapies are emerging with improved side effect profiles and efficacy. Biologic agents, such as belimumab and ustekinumab, have been promising in case studies but will require larger trials to establish their role in routine therapy. Other novel therapies that have been trialed successfully include spleen tyrosine kinase inhibitors and fumaric acid esters. Finally, new evidence has been published recently that describes safer dosing regimens in thalidomide and lenalidomide, both effective medications for CLE. Given the chronic disease course of CLE, long-term treatment-related side effects must be minimized, and the introduction of new steroid-sparing agents is encouraging in this regard.

22 February 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
HLHenry Lee
Henry Lee
TCTimothy L. Cowan
Timothy L. Cowan
BDBenjamin S. Daniel
Benjamin S. Daniel
Dedee MurrellDedee Murrell
Dedee Murrell
Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%–2% of the global population. Despite its well‐understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first‐line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time‐consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL‐23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL‐23 inhibitors for the treatment of vitiligo.

24 February 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
TATim Aung
Tim Aung
RNROWLAND NOAKES
ROWLAND NOAKES
Dedee MurrellDedee Murrell
Dedee Murrell
BDBenjamin S. Daniel
Benjamin S. Daniel
AKAwatef Kelati
Awatef Kelati

18 April 2024 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
ZHZachary Holmes
Zachary Holmes
PFPeter Foley
Peter Foley
CBChris Baker
Chris Baker
BDBenjamin S. Daniel
Benjamin S. Daniel

25 June 2025 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
CLConor Larney
Conor Larney
PFPeter Foley
Peter Foley
JWJason Wu
Jason Wu
BDBenjamin S. Daniel
Benjamin S. Daniel

10 September 2021 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
SRSarah Ringin
Sarah Ringin
CBChristopher S. Baker
Christopher S. Baker
PFPeter Foley
Peter Foley
BDBenjamin S. Daniel
Benjamin S. Daniel
ABA/Prof Chris Baker
A/Prof Chris Baker
BDBen Daniel
Ben Daniel